Catalogue Number: BS-5958R-CY3-BSS
|Shelf Life:||12 months|
|Preservative:||0.09% Sodium azide|
|Type:||Polyclonal Primary Antibody - Conjugated|
|Shipping Condition:||Blue Ice|
|Immunogen:||KLH conjugated synthetic peptide derived from human AF 4 protein|
Description: Proto-oncogene AF-4 (or FEL) is a product of a chromosomal aberration of the human gene AFF1, which is associated with acute leukemias. The fusion of AF-4 on chromosome band 4q21 with the mixed lineage leukemia (MLL or HRX) gene on 11q23 results in a MLL-AF-4 chimeric transcription factor in which AF-4 contributes transcriptional effector properties and requires cell-specific accessory factors. MLL is involved in several chromosomal translocations associated with acute myeloid and lymphoid leukemia. The MLL-AF-4 fusion protein is expressed in all normal hematopoietic cells. The expression of MLL-AF-4 influences the production of protein cyclin-dependent kinase inhibitor (CDKN1B), suggesting that inhibition of MLL-AF-4 expression may be a powerful and highly specific treatment of chemotherapy-resistant leukemia.
To ensure the best quality, Bioss primary antibodies are conjugated upon ordering. Please allow 2 weeks for this process.
AF 4; AF 4 protein; AF-4 protein; AF4/FMR2 family member 1; AFF 1; AFF1; AFF1_HUMAN; ALL1 fused gene from chromosome 4; ALL1-fused gene from chromosome 4 protein; FEL; MLLT2; MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA TRANSLOCATED TO 2; MLLT2; Protein AF-4; Protein FEL; Proto-oncogene AF4.